{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-091736","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2025-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.104625+00:00","generated_at":"2026-05-23T07:04:18.575385+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"confidence":"high","headline":"Indivior Q1 net revenue $266M, in line; GAAP EPS $0.38, non-GAAP $0.41; FY guidance unchanged","bullets":["Net revenue $266M (-6% YoY), in line with expectations; U.S. net revenue $222M (-8%).","SUBLOCADE NR $176M (-2% YoY); FY 2025 guidance unchanged at $725M-$765M.","GAAP diluted EPS $0.38 (down 15%); non-GAAP diluted EPS $0.41 (down 2%).","SG&A $132M (-8% YoY non-GAAP) reflects cost savings; FY non-GAAP SG&A guided $525M-$535M.","Revised prior financials to correct Branded Fee accrual (immaterial $6M overstatement in 2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-091736","json":"https://secwatch.observer/filing/0001193125-25-091736.json","markdown":"https://secwatch.observer/filing/0001193125-25-091736.md","text":"https://secwatch.observer/filing/0001193125-25-091736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000119312525091736/0001193125-25-091736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000119312525091736/d926381d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T07:04:18.575385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}